Lumida
/NRIX
⌘K
Nurix Therapeutics Inc

Nurix Therapeutics Inc

NRIX
$26.21USD-2.47%-0.66 today

MARKET CAP

2.7B

P/E (TTM)

FWD P/E

DAY RANGE

$26 – $27

52W RANGE

$8
$28

AI Summary

Stalk
StalkMedium

NRIX remains in a Stage 2 advancing structure with durable long- and medium-term uptrends, but current price is extended above key EMAs and shows overbought RSI and Options Score. Execution readiness is unfavorable at these levels; we defer entry and look to engage on a pullback into the rising 9/20EMA support area once acceptance is evident.

  • Phase 3 DAYBreak patient enrollment with Roche for CLL.
  • Roche partnership underpins pipeline credibility and future growth.
  • Q2 revenue of $9.04M and EPS -$0.81 missed consensus.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$29.8M$38.6M$77.0M$54.5M$84.0M
YoY %+66.9%+29.8%+99.3%-29.1%+54.0%
P / Sales41.6x15.6x4.4x26.4x17.5x
EV / Sales43.4x16.8x5.7x27.0x16.3x
Gross Profit, Adj.$29.8M$38.6M$77.0M$54.5M$84.0M
YoY %+66.9%+29.8%+99.3%-29.1%+54.0%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit43.4x16.8x5.7x27.0x16.3x
EBITDA, Adj.$-111.8M$-178.5M$-147.5M$-203.7M$-276.9M
YoY %-78.0%-59.7%+17.4%-38.1%-35.9%
Margin %-375.8%-462.2%-191.6%-373.4%-329.8%
EV / EBITDA-11.5x-3.6x-3.0x-7.2x-4.9x
EBIT$-117.9M$-183.9M$-155.1M$-213.0M$-285.7M
YoY %-81.4%-56.0%+15.7%-37.4%-34.1%
Margin %-396.3%-476.0%-201.4%-390.5%-340.2%
EV / EBIT-10.9x-3.5x-2.8x-6.9x-4.8x
Net Income$-117.2M$-180.4M$-143.9M$-193.6M$-264.5M
YoY %-171.0%-53.9%+20.2%-34.5%-36.6%
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (GAAP)-$2.73-$3.71-$2.65-$2.88-$3.05
YoY %+1.1%-35.9%+28.6%-8.7%-5.9%